Cymabay Therapeutics Inc Net Income per Employee (CBAY), current and historic results, rankings and more, Quarterly Fundamentals - CSIMarket
CSIMarket
 


Cymabay Therapeutics Inc   (NASDAQ: CBAY)
 

Cymabay Therapeutics Inc Net Income per Employee

CBAY's Quarterly Results, Trends, Rankings, Statistics
Cymabay Therapeutics Inc recorded a cumulative net loss of $-105 million during 12 month ending in the fourth quarter 2023.
The Healthcare sector has seen employees of 349 other companies achieving higher income per employee. While Cymabay Therapeutics Inc 's total ranking has deteriorated compared to the previous quarter from 2941 to 4387.


What is Income per Employee Ratio?






CBAY Net Income per Employee (Dec 31 2023)
IV. Quarter
(Sep 30 2023)
III. Quarter
(Jun 30 2023)
II. Quarter
(Mar 31 2023)
I. Quarter
(Dec 31 2022)
IV. Quarter
Y / Y Net Income Change - - - - -
Net Income per Employee (TTM) $ -1,549,559 -1,325,015 -1,187,118 -1,573,676 -1,558,838
CBAY's Total Ranking # 4387 # 2941 # 2551 # 2985 # 3156
Seq. Net Income Change - - - - -


CBAY Net Income per Employee Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 350
Healthcare Sector # 794
Overall Market # 4387

Net Income per Employee Statistics
High Average Low
$ -327,529 $ -1,023,672 $ -1,625,397
(Sep 30 2015)   (Dec 31 2019)







Companies with similar Income per Employee for 12 month ending Dec 31 2023, within Healthcare Sector Income per Employee Income 12 month ending Dec 31 2023Number of Employees Dec 31 2023


Date modified: 2026-09-18T13:11:05+00:00




Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.